WhaleCreep

Propel Bio Management, LLC 13F holdings, Q2 2025

Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →

Propel Bio Management, LLC disclosed 16 US equity positions worth $82.4m in its Q2 2025 13F filing. The largest position was PAGPEUR at 30.0% of the reported book, followed by ACHV and AKERO THERAPEUTICS INC. Against the Q1 2025 filing, it opened 2 new positions, added to 5 and reduced 2 among the top 16 holdings.

← Q1 2025 · Q3 2025 →

What did Propel Bio Management, LLC own in Q2 2025? Top 16 positions

#StockSectorWeightValueSharesΔ sharesvs Q1 2025
1 PAGPEUR PLAINS GP HOLDINGS LP-CL 30.0%$24.7m1,272,360 0% held
2 ACHV ACHIEVE LIFE SCIENCES INC 16.9%$13.9m6,153,091 151% added
3 AKERO THERAPEUTICS INC 14.8%$12.2m228,884 0% held
4 PHAT PHATHOM PHARMACEUTICALS I 10.7%$8.9m922,927 -19% reduced
5 ABEO ABEONA THERAPEUTICS INC Healthcare 6.7%$5.5m974,022 56% added
6 APLT APPLIED THERAPEUTICS INC 4.3%$3.5m11,285,420 0% held
7 MIST MILESTONE PHARMACEUTICALS 4.2%$3.5m1,791,557 23% added
8 DCTH DELCATH SYSTEMS INC 3.7%$3.1m226,052 27% added
9 TCRX TSCAN THERAPEUTICS INC 3.7%$3.0m2,087,139 0% held
10 ZVRA ZEVRA THERAPEUTICS INC 2.5%$2.0m231,874 29% added
11 CAPR CAPRICOR THERAPEUTICS INC Healthcare 0.8%$695.1k70,000 – new
12 MAAT PHARMA SACA 0.5%$452.1k94,181 -43% reduced
13 ATHIRA PHARMA INC 0.5%$450.8k1,492,792 0% held
14 72C EIGER BIOPHARMACEUTICALS 0.5%$423.0k146,381 0% held
15 WTS - Achieve Life Sci 0.0%$13.7k3,699,999 – new
16 CHINOOK THERAPEUTICS 0.0%$2.5k79,357 0% held

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.